US Food and Drug Administration officials agreed there is enough evidence that convalescent plasma “may be effective” and warranted an emergency use authorization, but argued more definitive data is necessary to pinpoint efficacy and the optimal populations that could benefit.
In a clinical memo, agency officials outlined the different and sometimes conflicting evidence that fed into its decision to...